Patents Assigned to LTB4 Sweden AB
  • Stabilized leukotriene B(LTB) agent pharmaceutical formulation
    Patent number: 8664271
    Abstract: The present invention relates to a novel pharmaceutical formulation comprising an LTB4 agent at an alkaline pH effective to stabilize the LTB4 agent and provide a formulation with an increased shelf-life. The formulation of the present invention has an increased shelf-life of at least 24 months.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: March 4, 2014
    Assignee: LTB4 Sweden AB
    Inventor: Pierre Borgeat
  • Crystalline leukotriene B
    Patent number: 8426469
    Abstract: Leukotriene B4, 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B4 (LTB4) are known in the art. The present inventors have discovered a crystal form of LTB4 and the present invention therefore relates to crystal forms of LTB4 in general, and the novel crystal form A of LTB4 in particular.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 23, 2013
    Assignee: LTB4 Sweden AB
    Inventor: Karol Horvath
  • LTBas vaccine adjuvant
    Patent number: 7914800
    Abstract: The present invention relates to a vaccine adjuvant for enhancing immune response of an individual to a vaccine, which comprises an immune-enhancing effective amount of an LTB4 agent in association with a pharmaceutically effective vaccine carrier.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: March 29, 2011
    Assignee: LTB4 Sweden AB
    Inventors: Louis Flamand, Jean Gosselin, Pierre Borgeat